Idenix Pharma (IDIX) – Press Releases
-
Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe
-
Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2013 Financial Results
-
Idenix Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
-
Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Patent Interference
-
Idenix to Raise $106.7 Million Through Registered Direct Offering
-
Idenix Pharmaceuticals Reports Sustained Virologic Response Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir (IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir
-
Idenix Pharmaceuticals Announces Declaration of Senior Party in a Second Patent Interference by the USPTO
Back to IDIX Stock Lookup
